IsoTherapeutics Group
IsoTherapeutics Group is a Texas-based radiopharmaceutical CDMO offering chelation, conjugation, radiolabeling, analytical, and cGMP manufacturing services to pharmaceutical and life-science customers. Founded in 2005, it operates as a wholly-owned subsidiary of Telix Pharmaceuticals following the April 2024 acquisition.
- Company typePrivate
- Founded2005
- HeadquartersAngleton, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What IsoTherapeutics Group does
IsoTherapeutics Group, LLC is a Texas-based contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals. Founded in 2005 by scientists R. Keith Frank, Ph.D. and Jaime (Jim) Simón, Ph.D., the company provides end-to-end development and manufacturing services spanning chelation chemistry, radiolabeling of proteins and antibody conjugates, conjugation, analytical testing, small animal pharmacokinetics/bio-distribution studies, kit development, and cGMP-compliant manufacturing for clinical trial-stage materials. The Angleton, Texas headquarters — 45 miles south of Houston — comprises three buildings including a 3,600 sq ft cGMP production facility with six controlled environment rooms, class 5 lead-shielded isolators, and a broad suite of radioanalytical instrumentation (alpha, beta, gamma counters; NaI well crystals with multichannel analyzers; Ge crystals for high-resolution gamma spectroscopy; liquid scintillation; HPLC with UV/RI/Rad; ICP; LC-MS; lyophilizer; autoclave; Siemens gamma camera). The facility operates under FDA 21 CFR Part 11 with a radioactive materials license covering numerous radioisotopes.
The company serves pharmaceutical and life-science customers developing therapeutic and diagnostic radiopharmaceuticals, alongside universities and medical centers conducting related research. Revenue is generated primarily through fee-for-service R&D and cGMP manufacturing contracts with agreed deliverables; consulting services draw on the founders' 100+ years of combined industry experience. Customer engagements span proof-of-concept work, preclinical studies, kit development, and clinical-stage manufacturing. Customers have included AstraZeneca, Pfizer, FUJIFILM Pharma US, Actinium Pharmaceuticals, Curium, NorthStar Medical Radioisotopes, RadioMedix, Progenics, Triad Isotopes, Advanced Accelerator Applications, Telix Pharmaceuticals, Excel Diagnostics, Serene, M.D. Anderson, and Dow Chemical. The company also developed the clinical-stage bone targeting radiopharmaceutical Sm-153 DOTMP, which was subsequently out-licensed to QSAM Biosciences via IGL Pharma Inc.
In April 2024, IsoTherapeutics was acquired by Telix Pharmaceuticals, an Australian-listed radiopharmaceutical company (ASX: TLX), and now operates as a wholly-owned subsidiary. Founder leadership — Frank as President/CEO and Simón as VP/CSO — was retained post-acquisition alongside board members, suggesting operational continuity and continued focus on radiopharmaceutical R&D and cGMP manufacturing services within Telix's broader diagnostic and therapeutic radiopharmaceutical portfolio.
IsoTherapeutics Group firmographics
Firmographics- Name
- IsoTherapeutics Group
- Legal name
- IsoTherapeutics Group, LLC
- Website
- https://isotherapeutics.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- IsoTherapeutics Group is a Texas-based radiopharmaceutical CDMO offering chelation, conjugation, radiolabeling, analytical, and cGMP manufacturing services to pharmaceutical and life-science customers. Founded in 2005, it operates as a wholly-owned subsidiary of Telix Pharmaceuticals following the April 2024 acquisition.
- Ownership category
- akta.pro rank
IsoTherapeutics Group industry classification
Industry- Product category
- Radiopharmaceutical CDMO / Contract Research & Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA), Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
Keywords
Where IsoTherapeutics Group is headquartered
LocationHeadquarters
- HQ city
- Angleton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
IsoTherapeutics Group business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
Revenue model
- Fee-for-Service R&D Services: The company performs fee-for-service early stage R&D meeting agreed upon deliverables. Services include radiopharmaceutical development, conjugation, radiolabeling, kit development and manufacturing, analytical services, small animal studies, pharmacokinetics/bio-distribution, target processing, radiochemical processing, and isotope selection. The company also provides consulting based on 100+ years of collective experience.
- cGMP Manufacturing Services: Manufacturing services for preclinical studies in cGMP facility, helping ensure seamless development of products from research to clinical trial-stage manufacturing
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
IsoTherapeutics Group product offering
Product offeringCore offering
IsoTherapeutics provides fee-for-service contract research and cGMP manufacturing for radiopharmaceuticals. Offerings cover chelation, conjugation, radiolabeling of proteins and antibody conjugates, analytical testing (GC, ICP, HPLC with Rad/UV/RI, radio-analytical counting), kit development and freeze-dried kit manufacturing, radiochemical and target processing, isotope selection, small animal studies, and pharmacokinetics/bio-distribution, supporting customers from proof of concept through preclinical cGMP manufacturing.
Product overview
IsoTherapeutics Group is a radiopharmaceutical development company offering an integrated portfolio of R&D and manufacturing services. The core offerings include radiolabeling, conjugation, chelation, and radiochemical processing services, complemented by cGMP manufacturing capabilities for clinical trial materials. The company also developed Sm-153 DOTMP, a clinical-stage bone targeting radiopharmaceutical. Services span from early-stage proof of concept research through to preclinical studies and clinical trial manufacturing under FDA guideline 21 CFR 11. The company was acquired by Telix Pharmaceuticals in April 2024.
Differentiator
Problem solved
Functional benefit
Products and services
- Radiopharmaceutical R&D Services Comprehensive research and development services for radiopharmaceutical development including radiolabeling, conjugation, chelation, and analytical services for early-stage drug development, supporting customers from proof of concept through preclinical studies.
- cGMP Manufacturing Services cGMP radiopharmaceutical manufacturing for clinical trials, performed in a 3,600 sq ft facility with six controlled environment rooms, class 5 lead-shielded isolators, laminar flow hoods, and lyophilizer capacity.
- Kit Development and Manufacturing Development and manufacturing of radiopharmaceutical freeze-dried kits for clinical use, supported by lyophilization capability within the cGMP facility.
- Pharmacokinetics / Bio-distribution Services Small animal studies and pharmacokinetic analysis performed to support pre-clinical proof of concept research for radiopharmaceutical programs.
- Radiochemical Processing Processing and handling of radioisotopes including target processing and isotope selection services performed under the company's radioactive materials license.
- Sm-153 DOTMP Clinical-stage bone-targeting radiopharmaceutical originally developed by IsoTherapeutics Group LLC, now owned by IGL Pharma Inc. and out-licensed to QSAM Biosciences.
Quantifiable outcome
- 100+ years combined scientific experience across the team
- +2 more outcomes
Companies that use IsoTherapeutics Group
Customer profileNamed customers14 records
Segments3 records
Ideal customer profiles2 records
IsoTherapeutics Group technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
IsoTherapeutics Group partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Telix PharmaceuticalscoreIsoTherapeutics was acquired by Telix Pharmaceuticals in April 2024. Telix is a radiopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals. The acquisition provides IsoTherapeutics with the backing of a larger pharmaceutical company while maintaining its operational identity.
- M.D. Anderson Cancer Research / HospitalminorCollaborative research partner in cancer research and hospital applications for radiopharmaceuticals
- The University of Missouri College of Veterinary MedicineminorAcademic research collaborator in veterinary radiopharmaceutical applications
- Advanced Accelerator ApplicationsminorCustomer and collaborator in radiopharmaceutical development services
- CuriumminorCustomer and collaborator in radiopharmaceutical development services
- RadioMedix, Inc.minorCustomer and collaborator in radiopharmaceutical development services
Scale indicators4 records
Recent moves4 records
Expansion highlights3 records
IsoTherapeutics Group competitors and assessment
Company assessmentDirect peers
- Curium: Global nuclear medicine company offering radiopharmaceutical manufacturing, radiolabeling, and contract development services for diagnostic and therapeutic agents — directly comparable to IsoTherapeutics' cGMP and radiochemistry service offering, and an existing customer/partner of IsoTherapeutics.
- PETNET Solutions (Siemens Healthineers): Operates one of the largest PET radiopharmaceutical manufacturing networks in the U.S. and Europe, providing cGMP-compliant production and distribution of PET tracers. Direct competitor for clinical-stage radiopharmaceutical manufacturing and CDMO services.
- NorthStar Medical Radioisotopes: U.S. producer of Mo-99 and other medical radioisotopes offering contract radiopharmaceutical development and manufacturing services. Comparable as a radiochemistry-focused CDMO serving overlapping pharmaceutical customers (and an existing customer of IsoTherapeutics).
- RadioMedix: Houston-based radiopharmaceutical company developing targeted diagnostic and therapeutic agents (including alpha-emitters) with in-house manufacturing capabilities. Closely comparable niche radiopharma CDMO/dev player and a current IsoTherapeutics customer.
Broad incumbents
- Advanced Accelerator Applications (Novartis): Subsidiary of Novartis and one of the largest radiopharmaceutical companies globally (Lutathera, Pluvicto), with significant in-house radioligand therapy manufacturing capacity. Comparable as a scaled radiopharma CDMO/developer with overlapping therapeutic and diagnostic capabilities.
- Lantheus Holdings: Commercial radiopharmaceutical company with a portfolio of diagnostic imaging agents (e.g., Pylarify, Definity) and a manufacturing network serving pharma customers. Comparable as a larger incumbent with similar radiopharma development and production capabilities.
- Cardinal Health Nuclear Pharmacy Services: Operates the largest U.S. radiopharmaceutical distribution and compounding network through its nuclear pharmacy services. Broad incumbent with overlapping radiopharma manufacturing, distribution and isotope-handling capabilities at much greater scale.
- GE Healthcare Pharmaceutical Diagnostics: Large incumbent in medical imaging diagnostics, including contrast agents and PET tracer manufacturing. Adjacent competitor for diagnostic radiopharmaceutical development and contract manufacturing partnerships with pharma.
Emerging players
- SHINE Radiochemicals: Emerging U.S. producer of medical radioisotopes (Mo-99, Lu-177) building out radiopharmaceutical development capabilities. Comparable as a niche radiochemistry player; existing supplier partner of IsoTherapeutics.
- Actinium Pharmaceuticals: Clinical-stage developer of targeted radiotherapies (alpha-emitters, including Iomab-B and Actimab-A) that uses external CDMOs like IsoTherapeutics for radiolabeling, conjugation, and cGMP manufacturing — representative of the emerging radiopharma sponsor segment IsoTherapeutics serves.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
IsoTherapeutics Group social profiles
Digital presenceIsoTherapeutics Group compliance and trust
Trust signalCompliance2 records
IsoTherapeutics Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
IsoTherapeutics Group leadership team
Management profileNumber of profiles
Profiles6 records
IsoTherapeutics Group funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IsoTherapeutics Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IsoTherapeutics Group
What does IsoTherapeutics Group do?
IsoTherapeutics provides fee-for-service contract research and cGMP manufacturing for radiopharmaceuticals. Offerings cover chelation, conjugation, radiolabeling of proteins and antibody conjugates, analytical testing (GC, ICP, HPLC with Rad/UV/RI, radio-analytical counting), kit development and freeze-dried kit manufacturing, radiochemical and target processing, isotope selection, small animal studies, and pharmacokinetics/bio-distribution, supporting customers from proof of concept through preclinical cGMP manufacturing.
Is IsoTherapeutics Group a public or private company?
IsoTherapeutics Group is a private company. It is classified as corporate owned and is currently acquired.
When was IsoTherapeutics Group founded?
IsoTherapeutics Group was founded in 2005. It employs 11 to 50 people.
Where is IsoTherapeutics Group based?
IsoTherapeutics Group is headquartered in Angleton, United States, in the North America region.
How does IsoTherapeutics Group make money?
Two revenue lines are on record. Fee-for-Service R&D Services are the primary driver. The others are cGMP Manufacturing Services.
Who are IsoTherapeutics Group's main competitors?
Direct peers on record are Curium, PETNET Solutions (Siemens Healthineers), NorthStar Medical Radioisotopes and RadioMedix. Broad incumbents are Advanced Accelerator Applications (Novartis), Lantheus Holdings, Cardinal Health Nuclear Pharmacy Services and GE Healthcare Pharmaceutical Diagnostics. Emerging players are SHINE Radiochemicals and Actinium Pharmaceuticals.
Does IsoTherapeutics Group have an API?
No public API is recorded for IsoTherapeutics Group.
What industry is IsoTherapeutics Group in?
IsoTherapeutics Group's product category is Radiopharmaceutical CDMO / Contract Research & Manufacturing. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers). Its NAICS code is 3254 and its SIC code is 2834.